Baird analyst Brian Skorney raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $81 and keeps an Outperform rating on the shares. The firm updated its model following the release of preliminary results which beat expecations on both earnings and guidance ahead of a busy 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $102 from $81 at H.C. Wainwright
- Mirum price target raised at Baird after preliminary results
- Mirum Pharmaceuticals price target raised to $95 from $88 at Baird
- Mirum Pharmaceuticals sees FY26 revenue $630M-$650M, consensus $595.94M
- Mirum Pharmaceuticals reports preliminary Q4 revenue $149M, consensus $135.72M